Illumina (ILMN) : Fcm Investmentstx reduced its stake in Illumina by 0.83% during the most recent quarter end. The investment management company now holds a total of 19,147 shares of Illumina which is valued at $2,661,242 after selling 160 shares in Illumina , the firm said in a disclosure report filed with the SEC on Oct 12, 2016.Illumina makes up approximately 1.52% of Fcm Investmentstx’s portfolio.
Other Hedge Funds, Including , Hollencrest Securities sold out all of its stake in ILMN during the most recent quarter. The investment firm sold 2,010 shares of ILMN which is valued $279,370.Advisory Services Network reduced its stake in ILMN by selling 981 shares or 10.67% in the most recent quarter. The Hedge Fund company now holds 8,215 shares of ILMN which is valued at $1,515,585. Illumina makes up approx 0.29% of Advisory Services Network’s portfolio.First Mercantile Trust Co reduced its stake in ILMN by selling 1,565 shares or 18.74% in the most recent quarter. The Hedge Fund company now holds 6,785 shares of ILMN which is valued at $1,251,765. Illumina makes up approx 0.17% of First Mercantile Trust Co’s portfolio.Private Asset Management Inc boosted its stake in ILMN in the latest quarter, The investment management firm added 1,170 additional shares and now holds a total of 7,547 shares of Illumina which is valued at $1,405,025. Illumina makes up approx 0.24% of Private Asset Management Inc’s portfolio.Washington Trust Bank reduced its stake in ILMN by selling 4 shares or 17.39% in the most recent quarter. The Hedge Fund company now holds 19 shares of ILMN which is valued at $3,537.
Illumina closed down -45.86 points or -24.81% at $138.99 with 1,10,33,440 shares getting traded on Tuesday. Post opening the session at $135.1, the shares hit an intraday low of $133.8 and an intraday high of $140.89 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Illumina reported $0.71 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.74. The company had revenue of $571.80 million for the quarter, compared to analysts expectations of $580.44 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.
Many Wall Street Analysts have commented on Illumina. Illumina was Downgraded by Citigroup to ” Neutral” on Oct 11, 2016. Shares were Reiterated by Cantor Fitzgerald on Oct 11, 2016 to “Hold” and Lowered the Price Target to $ 155 from a previous price target of $165 .Shares were Reiterated by Canaccord Genuity on Oct 11, 2016 to “Hold” and Lowered the Price Target to $ 136 from a previous price target of $165 .
Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.